Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788.

Immunomedics is a biopharmaceutical company that specializes in developing monoclonal antibody-based products for the treatment of cancer and other serious diseases. Its corporate objective is to become a fully-integrated biopharmaceutical company. The company was founded in 1982 and headquartered in Morris Plains, New Jersey.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

OSI Pharmaceuticals strives to improve the health and quality of life for patients, develop breakthrough treatment options for physicians, offer rewarding careers to employees, and deliver value to our shareholders. The strategy is to build on the success of our flagship product, Tarceva® (erlotinib), and continue to invest in clinical and pre-clinical drug candidates in oncology, diabetes and obesity to provide longer-term growth. OSI has evolved to become a scientifically strong and financially successful top-tier biopharmaceutical company that is focused on disease areas that impact virtually every family in the world. The Oncology team is dedicated to the discovery and development of molecular targeted therapies to revolutionize the way cancer is treated and improve treatment outcomes. The Diabetes & Obesity team is dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. The strategy for this business team is to advance a pipeline of innovative diabetes and obesity research projects through clinical proof-of-concept studies, with a view to then potentially seeking financially attractive development and commercialization partnerships for these research programs. The goal is to pave the way for the future of oncology, diabetes and obesity treatments. They believe that our Company strategy is poised to deliver a rich pipeline of promising drug candidates that have the potential to significantly improve the treatment options available to patients today.

UAB Research Foundation (doing business as UABRF), a subsidiary of The University of Alabama System, is a company headquartered in Birmingham, AL. The firm engages in identify, assess, and market commercially viable technology developed at The University of Alabama at Birmingham.

QIAGEN GmbH provides products for preanalytical sample preparation and molecular diagnostics solutions. It develops and markets consumable products and automated solutions to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. The company was founded in 1984 and is headquartered in Hilden, Germany.

CDI Bioscience, Inc. has developed an innovative technology for increased yield of bioproducts, manufactured in cellular systems. Genetic engineering technology is used to control the metabolism of cells, thus shifting the cell from explicative to production mode (RP Shift®). In particular, this technology has been designed for use in mammalian cells, unlocking their potential to produce proteins, peptides and enzymes. The current design of the technology can be readily translated to bacterial and yeast cellular systems for the production of commercial grade bio products.\nRecombinant therapeutic proteins have proven to be invaluable biopharmaceuticals for the treatment of chronic and life-threatening diseases. While exceptionally effective, the dosage requirements are generally very high for the required treatment. Several hundred milligrams of protein per administration is common and multiple doses are often required and being protein based drugs, they can only be produced by living cells which is why increasing production yield is a challenge.\nCDI Bioscience has developed a patented technology that dramatically improves the product yield in biopharmaceutical manufacturing. CDI's core technology, RP Shift®, solves a number of intermediate problems in the development of biopharmaceutical products by significantly boosting the productivity and viability of production cells.

Heyl Chemical-Pharmaceutical Factory manufactures, markets, and distributes pharmaceutical and medicinal products.

VTU Holding GmbH is an Austrian private company, with subsidiaries in AT. The firm provides engineering services.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Bayer CropScience NV, part of Bayer AG, is a Belgian company located in Diegem. The firm wholesales fertilizers and other agrochemical products. It was founded in 1972. Sylvain Moissionnier has been the CEO since 2020.

Bayer CropScience is one of the world’s leading innovative crop science companies in the areas of seeds, crop protection and non-agricultural pest control. People at Bayer CropScience are committed to help tackle challenges with their expertise in high value seeds, innovative chemical and biological crop protection solutions, and services for modern, sustainable agriculture. Their daily work – in the lab and on the ground – focuses on how they can help farmers across the globe overcome their challenges. With the “head of a scientist” and the “heart of a farmer” they bring innovative and inspiring solutions directly to their customers, along with reliable services and advice. And thus support food production where it begins: on the field.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Develops and supplies biotherapeutic proteins, plasmid DNA and antibody fragments

scienova GmbH provides laboratory dialysis solutions. The firm��s products include microdialyzer, gebaflex, protein A agarose and labelling solutions. The company was founded by Stefan Kreusch and Robert Fleischhauer in 2008 and is headquartered in Jena, Germany.

Oncogene Science, Inc. provided cancer diagnostics services. The company was founded in 1983 and was headquartered in Uniondale, NY.